Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now full pipeline small index

HER2/Neu Positive: full-pipeline trial registry

1 of 9 indexed HER2/Neu Positive trials are currently recruiting.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 1 currently recruiting · #1,916 of 28,707 conditions by registered trial count

HER2/Neu Positive: 9 US clinical trials tracked, 1 recruiting.

HER2/Neu Positive is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.

Enrollment posture brief

Registry condition her2neu-positive

OPEN 1 | RECR 11% | LATE 4 | EARLY 5 | RANK #1916 | SPON 4

Nearest open-share peer: Alcohol Use Disorders (11% recruiting · 9 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%HER2/Neu Positive (this)11%
Open-enrollment share among volume-matched conditions near HER2/Neu Positive

HER2/Neu Positive lists 1 open slots (11% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for HER2/Neu Positive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. HER2/Neu Positive is recruiting below its size-band peers.

    1 of 9 indexed trials (11.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates HER2/Neu Positive research.

    National Cancer Institute (NCI) accounts for 4 of 9 trials (44.4%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical HER2/Neu Positive enrolment sits around 92 participants.

    Median target enrolment is 92 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. HER2/Neu Positive research is mostly interventional.

    9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 22Phase 34

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3 491 participants

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

SWOG Cancer Research Network

NCT03418961

ACTIVE NOT RECRUITING Phase 2 92 participants

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

University of Nebraska

NCT01750073

ACTIVE NOT RECRUITING Phase 1 62 participants

Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer

National Cancer Institute (NCI)

NCT01327781

ACTIVE NOT RECRUITING Phase 2 40 participants

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

City of Hope Medical Center

NCT01273610

COMPLETED Phase 3 3,270 participants

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

National Cancer Institute (NCI)

NCT01275677

COMPLETED Phase 3 799 participants

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

National Cancer Institute (NCI)

NCT00785291

COMPLETED Phase 3 280 participants

Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

NCT00513292

COMPLETED Phase 1 37 participants

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

M.D. Anderson Cancer Center

NCT02152943

COMPLETED Phase 1 31 participants

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

University of Washington

NCT01922921

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2
Phase 3 4

Named interventions

Most-linked intervention names on HER2/Neu Positive records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Laboratory Biomarker Analysis Other
8 trials
Paclitaxel Drug
3 trials
Cyclophosphamide Drug
3 trials
Doxorubicin Hydrochloride Drug
2 trials
Epirubicin Hydrochloride Drug
1 trials
Polysaccharide-K Biological
1 trials
HER-2/neu Intracellular Domain Protein Biological
1 trials
Ixabepilone Drug
1 trials

US sites by state

Facility locations filed on HER2/Neu Positive trials. A trial with sites in several states counts in each.

California 5 trials
Arizona 3 trials
Arkansas 3 trials
Florida 2 trials
Alabama 2 trials
Alaska 2 trials
Washington 1 trials
Texas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this HER2/Neu Positive page

9 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HER2/Neu Positive condition card totals 9 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.